Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 14, 2014 01:05 ET | Source: Ablynx

ABLYNX TO PRESENT DATA ON ITS ANTI-IL-6R NANOBODY, DEVELOPED IN PARTNERSHIP WITH ABBVIE, AT THE AMERICAN COLLEGE OF RHEUMATOLOGY ANNUAL MEETING

GHENT, Belgium, Nov. 14, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced that it will present two posters on its novel anti-IL-6R Nanobody®, ALX-0061, at the 2014...
November 13, 2014 01:09 ET | Source: Ablynx

ABLYNX ANNOUNCES ITS BUSINESS UPDATE FOR THE FIRST NINE MONTHS OF 2014

REGULATED INFORMATION A period of good pipeline progress towards later stage clinical trials, a major alliance in the field of immuno-oncology and a strengthened financial position GHENT,...
November 06, 2014 01:06 ET | Source: Ablynx

ABLYNX TO PRESENT PRE-CLINICAL PROOF-OF-CONCEPT RESULTS WITH ANTI-RSV NANOBODY, ALX-0171, AT 9th INTERNATIONAL RESPIRATORY SYNCYTIAL VIRUS SYMPOSIUM

ALX-0171 has first-in-class potential for the treatment of RSV infections On track to start first-in-infant Phase IIa study before the end of 2014 GHENT, Belgium, Nov. 6, 2014 (GLOBE NEWSWIRE)...
October 23, 2014 01:07 ET | Source: Ablynx

ABLYNX'S ANTI-IL-6R NANOBODY PARTNERED WITH ABBVIE DEMONSTRATES A BIOAVAILABILITY OF MORE THAN 80% AFTER SUBCUTANEOUS INJECTION

GHENT, Belgium, Oct. 23, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced positive results from the Phase I bioavailability study of the subcutaneous formulation of its...
October 21, 2014 01:17 ET | Source: Ablynx

ABLYNX ANNOUNCES WARRANT EXERCISE

REGULATED INFORMATION GHENT, Belgium, Oct. 21, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree...
September 05, 2014 01:04 ET | Source: Ablynx

ABLYNX ESTABLISHES SPONSORED LEVEL I ADR PROGRAMME IN THE UNITED STATES

GHENT, Belgium, Sept. 5, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced the launch of a Sponsored Level I American Depository Receipt (ADR) programme in the United States in...
September 01, 2014 01:05 ET | Source: Ablynx

ABLYNX SIGNS EXCLUSIVE LICENSE AGREEMENT WITH EDDINGPHARM TO DEVELOP AND COMMERCIALISE ITS ANTI-TNFa NANOBODY IN GREATER CHINA

GHENT, Belgium, Sept. 1, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced that it has expanded its relationship with Eddingpharm, one of the leading Chinese specialty...
August 28, 2014 01:08 ET | Source: Ablynx

ABLYNX ANNOUNCES HALF-YEAR RESULTS FOR 2014

GHENT, Belgium, Aug. 28, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced its results for the six-month period ending 30 June 2014, which have been prepared in accordance with...
August 21, 2014 01:05 ET | Source: Ablynx

ABLYNX WILL ANNOUNCE ITS HALF-YEAR RESULTS FOR 2014 WITH WEBCAST

GHENT, Belgium, Aug. 21, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] will announce its half-year results for 2014 on Thursday 28 August 2014 at 7.00 am CET. The Ablynx management team...
August 13, 2014 01:04 ET | Source: Ablynx

ABLYNX AWARDED EU2.1 MILLION GRANT TO SUPPORT DEVELOPMENT OF NOVEL NANOBODIES(R) FOR OCULAR APPLICATIONS

GHENT, Belgium, Aug. 13, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced that it has been awarded a €2.1 million grant by the Flemish Agency for Innovation by Science...